Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Effect of study partner on the conduct of Alzheimer disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J.

Neurology. 2013 Jan 15;80(3):282-8. doi: 10.1212/WNL.0b013e31827debfe. Epub 2012 Dec 19.

2.

Donepezil for vascular cognitive impairment.

Malouf R, Birks J.

Cochrane Database Syst Rev. 2004;(1):CD004395. Review.

PMID:
14974068
3.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
4.

Omega-3 fatty acids for the treatment of dementia.

Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A.

Cochrane Database Syst Rev. 2016 Apr 11;4:CD009002. doi: 10.1002/14651858.CD009002.pub3. Review.

PMID:
27063583
5.

Rivastigmine for Alzheimer's disease.

Birks JS, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3. Review.

PMID:
25858345
6.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
7.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
8.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2003;(1):CD000442. Review.

PMID:
12535396
9.

Latrepirdine for Alzheimer's disease.

Chau S, Herrmann N, Ruthirakuhan MT, Chen JJ, Lanctôt KL.

Cochrane Database Syst Rev. 2015 Apr 21;(4):CD009524. doi: 10.1002/14651858.CD009524.pub2. Review.

PMID:
25897825
10.

Cholinesterase inhibitors for rarer dementias associated with neurological conditions.

Li Y, Hai S, Zhou Y, Dong BR.

Cochrane Database Syst Rev. 2015 Mar 3;(3):CD009444. doi: 10.1002/14651858.CD009444.pub3. Review.

PMID:
25734590
11.

Galantamine for Alzheimer's disease.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001747.

PMID:
15495017
12.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(1):CD001747. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD001747.

PMID:
11279727
13.

Rivastigmine for vascular cognitive impairment.

Birks J, McGuinness B, Craig D.

Cochrane Database Syst Rev. 2013 May 31;(5):CD004744. doi: 10.1002/14651858.CD004744.pub3. Review.

PMID:
23728651
14.

Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease.

Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, Peng D, Guo Q, Wu L, Chen S, Kuang W, Zhang J, Wei C, Tang Y.

Alzheimers Dement. 2017 May;13(5):592-597. doi: 10.1016/j.jalz.2017.01.007. Epub 2017 Feb 24.

PMID:
28238739
15.

Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee.

Swash M, Brooks DN, Day NE, Frith CD, Levy R, Warlow CP.

J Neurol Neurosurg Psychiatry. 1991 Feb;54(2):178-81. Review.

16.

Study partners should be required in preclinical Alzheimer's disease trials.

Grill JD, Karlawish J.

Alzheimers Res Ther. 2017 Dec 6;9(1):93. doi: 10.1186/s13195-017-0327-x. Review.

17.

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ.

Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6. Review.

18.

Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies.

Brondino N, Re S, Boldrini A, Cuccomarino A, Lanati N, Barale F, Politi P.

ScientificWorldJournal. 2014 Jan 22;2014:174282. doi: 10.1155/2014/174282. eCollection 2014. Review.

19.

Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting.

Robert PH, Konig A, Andrieu S, Bremond F, Chemin I, Chung PC, Dartigues JF, Dubois B, Feutren G, Guillemaud R, Kenisberg PA, Nave S, Vellas B, Verhey F, Yesavage J, Mallea P.

J Nutr Health Aging. 2013;17(8):653-60. doi: 10.1007/s12603-013-0046-3.

PMID:
24097018
20.

Currents of memory: recent progress, translational challenges, and ethical considerations in fornix deep brain stimulation trials for Alzheimer's disease.

Viaña JNM, Vickers JC, Cook MJ, Gilbert F.

Neurobiol Aging. 2017 Aug;56:202-210. doi: 10.1016/j.neurobiolaging.2017.03.001. Epub 2017 Mar 11. Review.

PMID:
28385550

Supplemental Content

Support Center